# Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

> **NCT03652376** · PHASE4 · UNKNOWN · sponsor: **University of Rostock** · enrollment: 20 (estimated)

## Conditions studied

- Severe Eosinophilic Asthma

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT03652376
- **Lead sponsor:** University of Rostock
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652376, "Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03652376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*